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Background: In a retrospective study we analyzed the impact of neoadjuvant chemotherapy (CTx) with the
PELF - protocol (Cisplatin, Epirubicin, Leukovorin, 5-Fluoruracil) on mortality, recurrence and prognosis of patients
with advanced gastric carcinoma, UICC stages Ib-III.
Methods: 64 patients were included. 26 patients received neoadjuvant CTx followed by surgical resection, 38
received surgical resection only. Tumor staging was performed by endoscopy, endosonography, computed
tomography and laparoscopy. Patients staged Ib – III received two cycles of CTx according to the PELF-protocol.
Adjuvant chemotherapy was not performed at all.
Results: Complete (CR) or partial response (PR) was seen in 20 patients (77%), 19% showing CR and 58% PR. No
benefit was observed in 6 patients (23%). Two of these 6 patients displayed tumor progression during CTx. Major
toxicity was defined as grade 3 to 4 neutropenia or gastrointestinal side effects. One patient died under CTx
because of neutropenia and was excluded from the overall patient collective. The curative resection rate was 77%
after CTx and 74% after surgery only. The perioperative morbidity rate after CTx was 39% versus 66% after resection
only. Recurrence rate after CTx was 38% and 61% after surgery alone; we detected an effective reduction of
locoregional recurrence (12% vs. 26%). The overall survival was 38% after CTx and 42% after resection only. The
5-year survival rates were 45% in responders, 20% in non - responders and 42% in only resected patients. A
subgroup analysis indicates that responders with stage III tumors may benefit with respect to their 5-year survival in
comparable patients without neoadjuvant CTx. As to be expected, non-responders with stage III tumors did not
benefit with respect to their survival. The 5-year-survival was approximated using a Kaplan-Meier curve and
compared using a log-rank test.
Conclusion: In patients with advanced gastric carcinoma, neoadjuvant CTx with the PELF- protocol significantly
reduces the recurrence rate, especially locoregionally, compared to surgery alone. In our study, there was no overall
survival benefit after a 5-year follow-up period. Alone a subgroup of patients with stage III tumors appear to benefit
significantly in the long term from neoadjuvant CTx.
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Gastric carcinoma is the second most common GI-cancer
with a poor overall prognosis [1]. Surgical resection is the
only curative treatment option in afflicted patients. Detri-
mentally, the overall resection rate is as low as 33%, and
in less than 60% of these patients R0-resection is possible
[2,3]. At the time of diagnosis, half of patients suffer from
advanced tumor disease making curative resection uncer-
tain at best [1,2]. The probability of lymph node metasta-
sis rapidly increases with the depth of infiltration. Already
patients with stage Ib tumors have a high likelihood of
lymph node metastases and therefore have a high recur-
rence rate of up to 69%, even following curative surgery
[1,2,4]. Locoregional recurrence is most common (87%),
but peritoneal and liver metastasis occur as well (13%)
[5,6]. These data dramatically illustrate the importance of
detecting gastric carcinoma at earlier stages.
The current survival rate across all tumor stages
ranges between 40% and 50% and is still achieved pri-
marily by curative surgical resection [7]. Only patients
with Ia-tumors have a reasonably good prognosis with a
5-year survival rate of 83%. The survival rates of patients
with more advanced tumors quickly decreases to 69% in
patients with Ib tumors, 43% in stage II, 28% in stage III
and 8.7% in stage IV patients [8-15].
Perioperative chemotherapy was thought to improve
this dire prognosis, especially in patients with advanced
tumor stages (UICC Ib-III) by down-staging the tumor
and increasing the rate of curative resection [1,2,16].
Intraoperative radiation or adjuvant radio-/chemother-
apy with various regimens do in fact successfully reduce
locoregional recurrence, but fail to improve the long-
term outcome [5,11-15].
Neoadjuvant chemotherapy (CTx) on the other hand
is believed to reduce intraoperative tumor cell dissemin-
ation as well as occult micrometastases. Strategically, it
is hoped that this may increase the curative resection
rate and reduce locoregional recurrence, thus improving
the prognosis of advanced gastric carcinoma [2,7,17].
Methods
From January 2000 to December 2006, we treated a total
of 124 patients with gastric carcinoma. All patients with an
early tumor stage (UICC Ia), distant metastases (liver or
peritoneum), oesophageal tumor localization, concomitant
active malignant disease or poor liver and kidney functions
and patients who denied CTx were excluded from our
study. 64 patients with stage Ib – III gastric carcinoma
were included. They received either a combined modality
treatment with neoadjuvant CTx and surgery or surgical
resection only. All patients chose chemotherapy after in-
formed consent. All data were assessed retrospectively.
Staging was performed using the AJCC/UICC classifi-
cation by means of endoscopy, endoscopic sonography,computed tomography and laparoscopy. The standard
surgical procedure consisted of total gastrectomy and
entailed D-2 lymphadenectomy. Subtotal gastrectomy and
D2-lymphadenectomy were restricted to early stages of
intestinal-type cancers of the distal third of the stomach.
The resection margins were examined by frozen sections
intraoperatively. Neoadjuvant CTx was administered ac-
cording to the PELF-protocol in two cycles at 0 and 6
weeks: Cisplatin 40 mg/m2, Epirubicin 35 mg/m2, Leucov-
orin 500 mg/m2 and 5-Fluoruracil 500 mg/m2. Chemo-
therapy was terminated in cases of gastrointestinal and
grade 2 to 4 hematologic toxicities. Subsequent to CTx, a
second CT-scan, endoscopy and endoscopic sonography
were performed to restage the tumor. Objective response
was evaluated by histological examination and classified as
“complete”, “partial” or “no response”. Histological regres-
sion was graded as “little”, “moderate” or “strong”. Both
groups were compared with respect to age, sex, symp-
toms, diagnosis, tumor localization (proximal/distal), hist-
ology (Lauren type and WHO classification), grading (low,
medium, high), extent of surgery (total/subtotal gastrec-
tomy), and resection status (R0/R1). Endpoint criteria
were complications during therapy, tumor recurrence and
survival. Furthermore, responders and non-responders
were compared with regard to completion of CTx, distri-
bution of tumor stages, resection status and long-term
survival (5-year follow-up). The 5-year-survival was ap-
proximated using a Kaplan-Meier curve and compared
using a log-rank test. Clinical follow-up spanned the time
from initial diagnosis of gastric cancer until the last regis-
tered visit in the clinical records of our ‘Comprehensive
Cancer Care Center Freiburg’ or the day of death. All
cases of postoperative death, including patients who died
of other causes, were included in the survival analysis.
All statistical calculations were performed using SPSS
15 (SPSS Inc., Chicago) software. Statistical analysis was
performed using X test, t test, and Fisher’s exact test. Re-
sults were considered statistically significant at P < 0.05.
Results
One Patient, who died under neoadjuvant chemotherapy,
was excluded. In total, 64 patients with advanced gastric
carcinoma staged UICC Ib-III were included in the study.
26 of these received preoperative CTx followed by surgical
resection. The other 38 patients received resection only.
Patient characteristics were well balanced in both groups
(Table 1). Median age was 67.86 years. There were 21
women and 43 men. Stage Ib was diagnosed in 12 patients
(19%), stage II in 20 (31%) and stage III in 32 (50%). The
tumor was located in the proximal stomach in 46 pa-
tients. Most frequently, an poorly differentiated (G3) in-
testinal Lauren type (36/64) tumor was found. All 64
patients underwent surgical Resection. 56 patients re-
ceived total gastrectomy with D2-lymphadenectomy, 8
Table 1 Patients characteristics (n = 64)
Neoadjuvant CTx Surgery n
(n = 26/64) (n = 38/64)
Age









Total gastrectomy 25 31
Subtotal gastrectomy 1 7
D2-lymphadenectomy 26 38
Resection
Curative (R0) 20 28







Signet-cell carcinoma 6 7
Grading
G 1-2 6 21




Table 2 Comparison of tumor stage distribution before
and after chemotherapy (downstaging) and resection
only
UICC Neoadjuvant CTx (n = 26/64) Surgery (n = 38/64)
Before CTx Postoperative Preoperative Postoperative
Ib 2 10 10 16
II 7 7 13 9
III 17 3 15 7




Surgery (n = 38/64)
Anastomotic leakage 3 4
Delayed nourishment 0 5
Intestinal obstruction 2 1
Wound infection 3 5
Pneumonia 1 6
Urinary infection 0 1
Lung embolism 0 2
Deep vein thrombosis 1 1
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tumor stages and intestinal-type tumors with distal
localization. The overall curative resection rate (R0) was
75% (n = 48/64). Thus by definition, 16 patients received
not curative resection (R1).
Preoperative CTx was administered in 26 and com-
pleted in 18 patients. In 8 cases, CTx was aborted due to
gastrointestinal toxicity, i.e. nausea, vomiting and diarrhea
(n = 3/26), hematologic toxicity, i.e. neutropenia (n = 2/
26), complete early tumor regression in one case and
tumor progression in 2 further patients. We observed a
histological response rate of 77% (n = 20/26), 5 patients
showing complete and 15 patients displaying partial re-
sponse. No histological benefit was detected in 6 patients
(23%). In respect of the regression grade 75% showed
submucosal subtotal cicatrisation, which complies withregressiongrade 2; the examination of the resected tissue
of the remaining patients showed complete necrosis.
(Regression grade was examined by JRSGC). The histo-
logical response was particularly significant among pa-
tients staged UICC III. Table 2 illustrates pre- versus
postoperative tumor staging in both groups. The curative
resection rate after neoadjuvant CTx was 77% (n = 20/26)
and was accomplished in 17 responders and 3 non-
responders. R1-resection was diagnosed in 6 cases (3 re-
sponders and 3 non-responders).
Postoperative complications developed in 35 of 64 pa-
tients. The complication rate was 39% in the group with
chemotherapy (n = 10/26) and 66% after surgical resec-
tion only (n = 25/38). Common complications like pneu-
monia (7/64), pulmonary embolism (2/64) and urinary
infection (1/64) occurred more frequently in the group
without neodjuvant CTx. Complication like deep vein
thrombosis appeared in both groups with the same fre-
quency (2/64). Between the two groups, there was no
difference with respect to the surgical complication rate,
which arose in 8 of 26 patients subsequent to CTx and
15 of 38 patients after resection only. Anastomotic leak-
age occurred in 12% after CTx and 11% after resection
only. Also intestinal obstruction (3/64), delayed nourish-
ment (5/64) and wound infection (8/64) weren’t more
frequent in the group with CTx (Table 3).
Overall recurrence rate was 52% (n = 33/64). CTx re-
duced the overall recurrence rate and was 39% in the
neoadjuvant group versus 63% in the only surgery group







Lymph node metastases 0 5
Distant metastases 4 5
Figure 2 Survival of responders, non-responders and only
resected patients (Log rank p = 0,283).
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after chemotherapy and occurred in 12% versus 26% after
resection only. Lymph node metastases merely occurred
in only resected patients. However, peritoneal recurrence
or distant metastases couldn’t be prevented by CTx.
The overall survival was not improved by CTx (Figure 1).
The 5-year survival rate was 38% after CTx versus 42%
after surgery only. Not even a subgroup analysis compar-
ing responders with only resected patients showed a bene-
fit of CTx. The 5-year survival rate of responders was 44%
versus the above mentioned 42% after surgery only.
Non-responders to CTx had a worse survival rate of
20% (Figure 2).
A subgroup analysis of patients with preoperative stage
III tumors showed a significantly improved survival in
responders to chemotherapy compared to patients with-
out response (p = 0.002) (Figure 3).
Discussion
The poor prognosis of gastric carcinoma has remained
unchanged for the past 2 decades with a 5-year-survivalFigure 1 Survival of patients with preoperative chemotherapy
versus surgery alone (Log rank p = 0,580).rate ranging between 40% and 50%. Surgery is the only
curative treatment option for locally advanced disease.
Furthermore, most patients are initially diagnosed at
advanced tumor stages. Despite curative resection (R0),
the overall recurrence rate is 69%. Locoregional relapseFigure 3 Survival curves of responders, patients without
neoadjuvant chemotherapy and non-responders to
neoadjuvant chemotherapy with stage III UICC only (log
rank p = 0,002).
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a high likelihood [1,4,6]. Radiation and chemotherapy aim
at controlling local tumor spread and eliminating dissemi-
nated tumor cells to prolong survival [18]. Intraoperative
radiation succeeded in reducing locoregional relapse, but
failed in improving overall survival [5]. The palliative im-
plementation of PELF-CTx had a significant impact on
the median survival [19]. Therefore, we investigated the
influence of this protocol in the neoadjuvant setting on
morbidity and mortality, tumor recurrence and prognosis.
Regarding size, our study ranges in the lower third of
current literature [1,2,5,20]. With respect to age (median
69 years), lack of specific symptomatology in early tumor
stages and typical symptoms in advanced stages of gastric
cancer, diagnosis/staging and tumor localization, our study
population compares well with similar trials [1,2,5,20].
Furthermore, our inclusion criteria are very similar to
comparable studies [1,2,20]. In our study, patients with
UICC stages Ib-III, diagnosed by imaging, were included.
In comparable trials, only patients with stage IV and M+
or only stages IIIa/b and IV were included [1,7,20].
Preoperative CTx aims at devitalizing and downsizing
tumor tissue to increase the chance of curative resection
[6]. In 20 patients (77%), there was an objective histo-
logical response. This is considerably more than in other
studies where histological response was observed in 17%
to 50% of cases [1,2,20-22]. An exceptional response was
observed in cases of UICC stage III tumors (Table 2). In
these patients a clear down-staging was recognizable
[2,6,20]. Following CTx, the curative resection rate was
77%, thus exceeding reported R0-resection rates of around
60% [2,20]. However, compared to the result in patients
who received surgical resection only (74%), we found no
significant difference.
A comparison of pre- and postoperative tumor staging
demonstrates a surprisingly low accuracy of implemented
diagnostics. In the group without CTx, only 7 cases of 15
diagnosed stage III tumors were verified histologically. In
the group with CTx, only 3 of 17 cases were confirmed
histologically. This effect may however be explained by a
down-staging of CTx. The similar high R0-resection rates
in both study groups may be indicative of diagnostic im-
precision, suggesting that more earlier tumor stages were
in the CTx group. Unfortunately, explaining this in retro-
spect proves unfeasible.
Preoperative CTx is hoped to reduce recurrence rates
(69%) by making curative resection more probable and
by eliminating micrometastases [2]. In our study, the
relapse rate was 38% after CTx versus 63% following
surgery. Other studies report recurrence rates of 60% to
70% following CTx [5,20]. Especially local recurrence
seems to be reduced after preoperative chemotherapy.
26% after surgery only and 12% of patients with CTx
developed locoregional recurrence. These results arecomparable with the local relapse after intraoperative
radiation (10%) [5]. Recurrence in lymph nodes was only
seen in patients without CTx and is explainable by the ob-
served response especially of lymphatic micrometastases
[20,22]. Nevertheless, recurrence in the peritoneum, 12%
after CTx and 20% after surgery, and liver metastases
couldn’t be prevented and were comparable with other
trials [23].
First and foremost, neoadjuvant CTx aims prolonging
overall survival [6]. Unfortunately, our results show that
the overall survival is not improved under these condi-
tions. The 5-year survival rate with chemotherapy was
38% versus 42% without. A comparable trial failed to show
a benefit of chemotherapy as well [2,20]. Current trials
hypothesize that an objective histological response is an
important prognostic factor [2,6]. However, in our study
responders had no better long-term outcome than pa-
tients without CTx (45% versus 42%) (Figure 2) [2,6,20].
The only exception to our observation was seen in a sub-
group analysis of responders with stage III tumors. In this
subgroup, the 5-year survival rate was 46% after CTx ver-
sus 31% after resection only (Figure 3).
Conclusion
We regard advanced gastric cancer as a systemic disease.
Meaningful prognostic criteria are intraperitoneal and
local recurrence. Neoadjuvant CTx succeeds in reducing
local relapse, but does not appear to impact the overall
survival. Despite this lack of benefit as seen across all
tumor stages, a subgroup of patients with stage III tumors
seems to benefit significantly from neoadjuvant CTx.
However, it remains challenging to select these patients
due to the low accuracy of current diagnostics. In sum-
mary, additional therapeutic modalities, such as antibody
treatment in combination with current standards of treat-
ment will be necessary to improve the prognosis of ad-
vanced gastric cancer.
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